For security reasons and to continue to access your member area, we thank you for validating your member account by clicking on the following link:
I validate my member account
You will receive an email at the address indicated when you created your account.
Then click on the link in the email. You will then be able to access your member account again.
If you have not received this email,
8 characters minimum
1 special character
Different from your nickname
Both passwords are the same
Benefit from additional features and services free of charge.
become a member
New to Boursorama?
become a member
(CercleFinance.com) – Oddo BHF maintains its ‘outperformance’ recommendation on Quantum Genomics, but adjusts its price target from 12 to 10.5 euros, after the publication on Friday by the biotechnology company of the results of the QUORUM study .
‘The efficacy of firibastat is equivalent to ramipril in heart failure, but shows greater efficacy in severe patients, safety in use and anti-hypertensive action’, summarizes the analyst in charge of the dossier.
The design office reduced its price target for the title by lowering its peak sales in the indication, from 1.2 billion to 822 million euros for marketing in 2026 (against 2025), and a POS maintained at 30%.
This analysis was prepared by Cercle Finance and disseminated by BOURSORAMA on 08/30/2021 at 09:45:00.
Acting exclusively as a distribution channel, BOURSORAMA did not participate in any way in its development nor exercised any discretionary power with respect to its selection. The information contained in this analysis has been transcribed “as is”, without any representation or warranty of any kind. The opinions or estimates expressed therein are those of its authors and do not reflect the point of view of BOURSORAMA. Subject to applicable laws, neither the information contained nor the analyzes expressed therein can engage BOURSORAMA’s responsibility. The content of the analysis made available by BOURSORAMA is provided for information only and has no contractual value. It thus constitutes a simple decision aid over which the user retains absolute control.
BOURSORAMA is a credit institution under French law approved by the Prudential Control and Resolution Authority (“ACPR”) and by the Financial Markets Authority (“AMF”) as an investment services provider and under the prudential supervision of the European Central Bank (“ECB”).
In accordance with the regulations in force, BOURSORAMA establishes and maintains operational a conflict of interest management policy and implements administrative and organizational measures to prevent, identify and manage conflict of interest situations with regard to the recommendations of investment broadcast. These rules notably contain provisions relating to personal financial transactions in order to ensure that BOURSORAMA employees are not in a situation of conflict of interest when Boursorama issues investment recommendations.
The reader is informed that BOURSORAMA has no conflict of interest that could affect the objectivity of the analyzes disseminated. As such, the reader is informed that there is no direct link between the analyzes disseminated and the variable remuneration of BOURSORAMA employees. Likewise, there are no financial or capital links between BOURSORAMA and the issuers concerned, apart from the contractual commitments that may govern the provision of the broadcasting service.
It is recalled that the entities of the Societe Generale group, to which BOURSORAMA belongs, may carry out transactions on the financial instruments mentioned in this analysis, hold stakes in the companies issuing these financial instruments, act as market maker, advise , broker, or banker of these instruments, or be represented on the board of directors of these companies. These circumstances can in no way affect the objectivity of the analyzes disseminated by BOURSORAMA.
You must be a member to add a comment.
Already a member ?
Not a member yet ?
Join for free